G!T*G@W8O(QIXRKG0?6]MS.;.]W6RQISI
M:[E!05^64N7,T%6M?+U1R%('RKD?!4''SUDFO$'/OWAF<"9PKT-L^9
M>AXAE_N^%WHO#Y^SU=K8!W_0V[ 5SM%\W#<-
M'I5-"SP\
MOVC_S3E/SBR8QK'DW[/4K/M>UX,4EVS+S6>Y_QU+A]I67R*Y=K^P+V4##Y*M
M-C(OP<0@ST3QSY[*0!P 2$\]("H!T6M ZPU 7 +B FS+!!3\D]*"M-VNS!1=^A*5Z9L(4R-XJ^9H0S@[F1R>/5B$*=PECF5'^:
MN0Q>P3!-,WMD'.Y%49+VP\4$#H0"[A
MKXTEHC_")V)B:DMG5.AJ.UVV?^X&%)3=83)/)2)JN*^D)F=)3=^3.G*X73G<
M;G3XN^M[%-;A#A7U<9@^H4HRC3!368)U7A<*.P<\XD[WM4OO"!UQ[51<.XU<
M/Z$@CARH$U KH=:5::.8'0O$VM8.PH\'M EL*H6;RMK-KU&;W8I0M]'](>#!;PV;/BYE(_2F1>4Y4M L%V]'\
M9 N.0%,55K9CP04-SF*$7M:.S?"TG;3CTTR_+U>XXA]L##FJE5O5--'<"E,,
MA.JU6@>';@EZ]3X*[\9AS?O$KH]N0_FIOM@]'YA:94(#QR69"JYOB*PJUKGB
M8N3&[2L+:6C[<<&PO=V]R:W-H965TBG?"FQY]8L$4LA4TQD1$(\<6;=F\70Q-N 9P9[==0FQLE&B)WI
M_(@FCF<$ 8=0&P:*GQ=8 .>&"&7\J3B=>DD#/&Z_L=];[^AE0Q4L!/_)(IU,
MG)%#(HAIP?5*[+]#Y:=O^$+!E?TE^RK6ZNYK@1$5F(% ^'HG9_K\@:3TQ4<" B)C.%:<[-A")/)E8+LJ \+#C50.XI
MD^29\L+&/E9QWR3-=!EZE^9<' 4^7P+FC+^9>QJ5&\TN&&E=%XJ]<\HO28/
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M!S#]"U!+ P04 " #B@V13Q-01-,\" "Y!P &0 'AL+W=O0 EKP(+LTPR*TMKL+0
M)#D(:LY4 1)W,J4%M3C5J] 4&FCJ08*'<11]"@5E,A@-_-I\9;_QN6,N2VI@HO@/EMI\&%P$)(6,EMP^JLUGJ//Q 2:*&_\DF_IL%)"D
M-%:)&HP1"":K-WVI?=@!($\[(*X!\7M ;P^@6P.ZQRKT:D#O6(5^#?"IAU7N
MWK@IM70TT&I#M#N-;&[@W?=H](M)5R<+JW&7(I6*_F0*EC)^BCK&+9CMBTGR-5>E03$S""WFZ"(-DSJ?
M<95/O">?+KE7TN88G,3(6O#3P_C+ _@0O6T,CK<&C^.#A LHSD@W^D#B*.ZT
MQ#,Y'AZUI?-_ZK-_5G]C1K>IMJ[GZ^WA:ZLBJ\B\U$F.?WM3@%8ES^3I'L02
M],\#NKU&M^=UNWMTKZ5EJ2M(O)3( I)2,\M@IX)OWE?P0T9F5$L,U.P4[=,=
M$I-;"\(<"JO?A-4_V@[U:D>QM2.I[##.CK9?H6+O>W;7$-:CSOGYQ2!<[]97
MRZ&+R\NWAZ;',,W^PE19$.[<10+TRC;:7Z_OUL>=JTFG
M97V*?:EJ(Z_T55.[IWK%T$(.&4I%9^<8JJX:136QJO WX5)9O%?],,?>"MH=
MP/U,*;N=.(&F6X_^ %!+ P04 " #B@V13 ::]OD" #U"0 &0 'AL
M+W=O@!]H:VT0D4B7I)7_?(24K3B(K[H)<;)*:]][,X]K9"OF@5@":
M[.*(JZZSTCJY[>@M%S/]5HROB1],VU,,U#D$^F'(3.322-RP],E::;V? 2:LN@"(^ZF(W+^
M\:+C:LS$\+GS3'60J@9'5*MD++A>*7+-0P@+\*-R?+L$[Z(#N0W!WH9!4$HX
MA:1"JMXE";S +\AG>#K<*RKGW]2O_UK]F1G5?$U4+5_UI#4Q%$J3/@\)#H/<
M +G_BO'D1D.L?I:HU7*UFE6KG:0&.SP"%:BB-97R-"R/.0 W/:QV6N"$/N+)JA7!/81GZT&U15-=?R5?;WO>D10:>0J-TA3&
M=,?B=4SNQQ#/0)9-6S.G;+[#(FGE:JW_Y^&P]C"([N<&^VKD.;EA[,SXU]1NN[!-1:#7-KW@R)SE-;IZ96/YF^4OKV97XP/
M_*NA7S ^,F\:>VT^T:EN
M&7\6,8!$+VE"1<^*I5QW;%N$,:187+,U4+6S9#S%4DWYRA9K#C@RH#2Q/<<)
M[!03:O6[9FW*^UV6R810F'(DLC3%_'4("=OV+-?:+YWUW@%L&PM%L,19
M(F=L^Q.*@'SM+V2),+]H6]@Z%@HS(5E:@)6"E-#\BU^*1!P E)]J@%< O/>
MYA% HP TSF5H%H#FN0Q^ 3"AVWGL)G%C+'&_R]D6<6VMO.F!R;Y!JWP1J@ME
M+KG:)0HG^S,0DF>AS#BA*S30?QN1! 3ZCN9Y[2"V1*,8\Y5:G$&")41(,G04
M>#$&B4ERJ3P\S,?HXMMEUY9*J>:SPT+5,%?E'5'50/>,REB@"8T@JL"/Z_'M
M&KRM,E2FR=NE:>C5.IS#^AHUG"OD.9Y;H6=T/MRI"N=S[)-_9G^3C$99,PWC
MKW%6S8R8D&A (UT1P#> GNZ4/;J5D(K?-6S-DJUIV)I'V 9AR#.(WA7=UWY1+*U:2L63*HFQ0QC
MU:D"UP9J?\F8W$TT0=G[]O\"4$L#!!0 ( .*#9%.]O@E*_P( (D/ -
M >&PO<'J]IE1[7<5%
MD_IKK>L/0="LUK0BS9FLJ3!((55%M)FJ,FAJ14G>@%/%@^ED$@<58<)?S$5;
M75:Z\5:R%3KUIZ/)L[?/>>J'\3O?LW29S&GJWYZ^_M%*??'*L_>3MR,+[9U$9AJ<@FG)[[.X?^9H(LIN][<<#=%7N[
M.H$]%>/0"!J&EL9.@'^?S7+OT1>O5[$[J3ZW)1O1SZ!5ZI6C!NG[>%6-\
MC#W$V4E=\\U'SDI149O[DP,NYF3KYZVE8O"_G@=3Q:/3CV4O\;'+%\%]1;MHQK)H;9FN4Y%0_>RH9>DZ7Y
M/^. WZS/:4%:KF]&,/5WXZ\T9VV5C*NNH!##JMWX"Z07QN.9:V(QD=..YMDP
M5>6R'WIF8*(.%S@<(Y?]Y48P'XNY$<"P.)@"S,=Z87'^IWQF:#X6P[3-G,@,
M]9FA/M;+A63]!XOC]DG,Y2N'<;BP,>V"Y@O0/QW7&@I]P^
M402[BFG#GF <21(,@5YT]V@<(]6)X>/>'^PIB:(D<2. N15$$8; TX@CF +0
M@"%1U)^#1^=1L#VG@MV/[\4O4$L#!!0 ( .*#9%.7BKL
M-8?20$3;8T.P6BP^0"X99K>]9!:GEDUC2GF(
M(O'<14(LHHCKRG6FU,*Q*]OA]>L9)UOAJMO17JR>$C_B?)[$\SDY?K7N>6KM
M,WMKM/'C8A["XJ@LO9Q#(_P/NP"#+3/K&A&PZ)Y*OW @:C\'"(TN^6 P*ANA
M3'%RO!SKSI5IP0:005F#E;'B4<&K_VJ/1?:BO)HJK<+[N.C.-12L448UZ@/J
M<3$HF)_;UU_6J0]K@M 3Z:S6XZ+J&Q[!!277JB<1\D%,?5<3Q/1>(,BX& UP
MP)ER/G0]NO$%,KX =NY+;;!72@=P%R+ 3V?;A3)/<1B<19E,HXO#\M@'\F'PK[QIGB
MK:_K?M8!<9,8NB.%#>ZZ[L#S09Y;4X/Q4#,\\U:K&CEJ=B:T,!)8 LD)2+Y%
MR#\\@=PE('>W CF).'AI CDD((=;A%R)Y!X!N;=-R-T$4! 'N2%
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MR2=02P,$% @ XH-D4]JP!6U2 0 _A$ !H !X;"]?LB+:UX9S7&GF=&Y_M@_C/1EF53F$];?'>F
M]W\,UC]VO+K:&*^BPC:AP^B&&6,!22]8"U
M:T*N28#7A&"3 +$)R28!9A.B30+4)F2;!+A-"#<)D)N0;A)@-R'>)$!O1KU9
M@-Z,>K, O?GE95N WHQZLP"]&?5F 7HSZLT"]&;4FP7HS:@W"]";46\6H#>C
MWOQ.O9V_M\8M/8\U?F"_DVH_W6N6Q\_+QR;BG,PX:_C=<_P%4$L#!!0 (
M .*#9%-6#%%4?P$ ,,2 3 6T-O;G1E;G1?5'EP97-=+GAM;,V8RT[#
M,!!%?R7*MFI<&R@/M=T 6^B"'S#)I+'JEVRWM'_/)'U(H!)1%8G9Q$H\<^^U
M1SJ+3-ZV'F*V,=K&:=ZDY!\8BV4#1L;">;"X4[M@9,+7L&!>EDNY "9&HS$K
MG4U@TS"U&OEL\@2U7.F4/6_PUU#"*J";"Y#>I$&J]A&LYBV&F+1+W$B
MHZMK54+ERI7!EB+Z +**#4 RNMB)#OJ=$]XP[)[\8O].IL\0*^?!^8@3"W"^
MW6$D;??0HQ"$I/J/>'1$Z8O/!^VT*ZA^Z8W7^^'"LIM'9-UR^1U_G?%1_\P<
M@DB.*R(YKHGDN"&28TPDQRV1''=$X K @ $0 @ &O 9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4 " #B@V13F5R<(Q & "<)P $P
M @ ', 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( .*#9%.
M?[:4504 ! 6 8 " @0T( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @
MXH-D4_9E"\W! @ 2PD !@ ("!*!( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ XH-D4],-_7R6 @ 6 8 !@ ("!
M-S@ 'AL+W=O&UL4$L! A0#% @ XH-D4V5^F>%3! @@H !D
M ("!Q#T 'AL+W=O&PO=V]R:W-H
M965T&UL4$L!
M A0#% @ XH-D4[[ADN;9 @ 5 8 !D ("!1TH 'AL
M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ XH-D
M4Z&H6.:7 @ ZP4 !D ("!^E< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ XH-D4]J2OQ:G @ 08
M !D ("!M& 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ XH-D4\06*Y!" @ #@4 !D
M ("!<6T 'AL+W=O&PO=V]R:W-H965T
M&UL4$L! A0#
M% @ XH-D4XBD 6K9 @ #0@ !D ("!:W8 'AL+W=O
M0 >&PO=V]R:W-H965T&UL4$L! A0#% @ XH-D4WS,
M=-P? P !PL !D ("!L7\ 'AL+W=O&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #B
M@V135@Q15'\! ##$@ $P @ 'CBP 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08 )0 E /H) "3C0 !
end
XML
42
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
43
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
XML
44
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.21.2
html
89
194
1
false
24
0
false
4
false
false
R1.htm
100000 - Document - Document and Entity Information
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation
Document and Entity Information
Cover
1
false
false
R2.htm
100010 - Statement - Condensed Consolidated Balance Sheets
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets
Condensed Consolidated Balance Sheets
Statements
2
false
false
R3.htm
100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical
Condensed Consolidated Balance Sheets (Parenthetical)
Statements
3
false
false
R4.htm
100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income
Statements
4
false
false
R5.htm
100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity
Condensed Consolidated Statements of Stockholders' Equity
Statements
5
false
false
R6.htm
100050 - Statement - Condensed Consolidated Statements of Cash Flows
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows
Condensed Consolidated Statements of Cash Flows
Statements
6
false
false
R7.htm
100060 - Disclosure - Nature of the Business
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusiness
Nature of the Business
Notes
7
false
false
R8.htm
100070 - Disclosure - Summary of Significant Accounting Policies
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies
Summary of Significant Accounting Policies
Notes
8
false
false
R9.htm
100080 - Disclosure - Fair Value of Financial Instruments
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstruments
Fair Value of Financial Instruments
Notes
9
false
false
R10.htm
100090 - Disclosure - Accounts Payable, Accrued Expenses and Other
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther
Accounts Payable, Accrued Expenses and Other
Notes
10
false
false
R11.htm
100100 - Disclosure - Stock-Based Compensation
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensation
Stock-Based Compensation
Notes
11
false
false
R12.htm
100110 - Disclosure - Net Loss Per Common Share
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShare
Net Loss Per Common Share
Notes
12
false
false
R13.htm
100120 - Disclosure - Restructuring Activities
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivities
Restructuring Activities
Notes
13
false
false
R14.htm
100130 - Disclosure - Recent Accounting Pronouncements
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRecentAccountingPronouncements
Recent Accounting Pronouncements
Notes
14
false
false
R15.htm
100140 - Disclosure - Summary of Significant Accounting Policies (Policies)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies
Summary of Significant Accounting Policies (Policies)
Policies
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies
15
false
false
R16.htm
100150 - Disclosure - Fair Value of Financial Instruments (Tables)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables
Fair Value of Financial Instruments (Tables)
Tables
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstruments
16
false
false
R17.htm
100160 - Disclosure - Accounts Payable, Accrued Expenses and Other (Tables)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherTables
Accounts Payable, Accrued Expenses and Other (Tables)
Tables
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther
17
false
false
R18.htm
100170 - Disclosure - Stock-Based Compensation (Tables)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationTables
Stock-Based Compensation (Tables)
Tables
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensation
18
false
false
R19.htm
100180 - Disclosure - Net Loss Per Common Share (Tables)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShareTables
Net Loss Per Common Share (Tables)
Tables
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShare
19
false
false
R20.htm
100190 - Disclosure - Restructuring Activities (Tables)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesTables
Restructuring Activities (Tables)
Tables
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivities
20
false
false
R21.htm
100200 - Disclosure - Nature of the Business - Additional Information (Detail)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail
Nature of the Business - Additional Information (Detail)
Details
21
false
false
R22.htm
100210 - Disclosure - Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail
Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail)
Details
22
false
false
R23.htm
100220 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail
Fair Value of Financial Instruments - Additional Information (Detail)
Details
23
false
false
R24.htm
100230 - Disclosure - Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail
Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail)
Details
24
false
false
R25.htm
100240 - Disclosure - Stock-Based Compensation - Additional Information (Detail)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail
Stock-Based Compensation - Additional Information (Detail)
Details
25
false
false
R26.htm
100250 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail
Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail)
Details
26
false
false
R27.htm
100260 - Disclosure - Net Loss Per Common Share - Schedule of Outstanding Options Excluded from Computation of Diluted Income (Loss) Per Share (Detail)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingOptionsExcludedFromComputationOfDilutedIncomeLossPerShareDetail
Net Loss Per Common Share - Schedule of Outstanding Options Excluded from Computation of Diluted Income (Loss) Per Share (Detail)
Details
27
false
false
R28.htm
100270 - Disclosure - Restructuring Activities - Additional Information (Detail)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail
Restructuring Activities - Additional Information (Detail)
Details
28
false
false
R29.htm
100280 - Disclosure - Restructuring Activities - Summary of Charges Related to Restructuring Activities (Detail)
Sheet
http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesSummaryOfChargesRelatedToRestructuringActivitiesDetail
Restructuring Activities - Summary of Charges Related to Restructuring Activities (Detail)
Details
29
false
false
All Reports
Book
All Reports
mack-10q_20210930.htm
mack-20210930.xsd
mack-20210930_cal.xml
mack-20210930_def.xml
mack-20210930_lab.xml
mack-20210930_pre.xml
mack-ex311_8.htm
mack-ex312_7.htm
mack-ex321_6.htm
mack-ex322_9.htm
http://fasb.org/us-gaap/2021-01-31
http://xbrl.sec.gov/dei/2021
http://fasb.org/srt/2021-01-31
true
true
JSON
47
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"instance": {
"mack-10q_20210930.htm": {
"axisCustom": 0,
"axisStandard": 14,
"contextCount": 89,
"dts": {
"calculationLink": {
"local": [
"mack-20210930_cal.xml"
]
},
"definitionLink": {
"local": [
"mack-20210930_def.xml"
]
},
"inline": {
"local": [
"mack-10q_20210930.htm"
]
},
"labelLink": {
"local": [
"mack-20210930_lab.xml"
]
},
"presentationLink": {
"local": [
"mack-20210930_pre.xml"
]
},
"schema": {
"local": [
"mack-20210930.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.sec.gov/country/2021/country-2021.xsd",
"https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
"https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
"https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
"http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
"https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
"https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
"https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
"https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
"https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
"https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
"https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
]
}
},
"elementCount": 223,
"entityCount": 1,
"hidden": {
"http://fasb.org/us-gaap/2021-01-31": 4,
"http://xbrl.sec.gov/dei/2021": 7,
"total": 11
},
"keyCustom": 15,
"keyStandard": 179,
"memberCustom": 14,
"memberStandard": 10,
"nsprefix": "mack",
"nsuri": "http://www.merrimackpharma.com/20210930",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"p",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "100000 - Document - Document and Entity Information",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation",
"shortName": "Document and Entity Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100090 - Disclosure - Accounts Payable, Accrued Expenses and Other",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther",
"shortName": "Accounts Payable, Accrued Expenses and Other",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100100 - Disclosure - Stock-Based Compensation",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensation",
"shortName": "Stock-Based Compensation",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100110 - Disclosure - Net Loss Per Common Share",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShare",
"shortName": "Net Loss Per Common Share",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100120 - Disclosure - Restructuring Activities",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivities",
"shortName": "Restructuring Activities",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100130 - Disclosure - Recent Accounting Pronouncements",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRecentAccountingPronouncements",
"shortName": "Recent Accounting Pronouncements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100140 - Disclosure - Summary of Significant Accounting Policies (Policies)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
"shortName": "Summary of Significant Accounting Policies (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100150 - Disclosure - Fair Value of Financial Instruments (Tables)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables",
"shortName": "Fair Value of Financial Instruments (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100160 - Disclosure - Accounts Payable, Accrued Expenses and Other (Tables)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherTables",
"shortName": "Accounts Payable, Accrued Expenses and Other (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100170 - Disclosure - Stock-Based Compensation (Tables)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationTables",
"shortName": "Stock-Based Compensation (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100180 - Disclosure - Net Loss Per Common Share (Tables)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShareTables",
"shortName": "Net Loss Per Common Share (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210930",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100010 - Statement - Condensed Consolidated Balance Sheets",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
"shortName": "Condensed Consolidated Balance Sheets",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210930",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100190 - Disclosure - Restructuring Activities (Tables)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesTables",
"shortName": "Restructuring Activities (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210930",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RetainedEarningsAccumulatedDeficit",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100200 - Disclosure - Nature of the Business - Additional Information (Detail)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
"shortName": "Nature of the Business - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:NatureOfOperations",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_deiLegalEntityAxis_mackCelatorPharmaceuticalsIncMember_20200327",
"decimals": "-5",
"lang": null,
"name": "mack:CashPaymentReceived",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100210 - Disclosure - Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail",
"shortName": "Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:LiabilitiesFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100220 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail",
"shortName": "Fair Value of Financial Instruments - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:LiabilitiesFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210930",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AccountsPayableCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100230 - Disclosure - Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail",
"shortName": "Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210930",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AccountsPayableCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210701_20210930",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100240 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
"shortName": "Stock-Based Compensation - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210701_20210930",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": "4",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlipure",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100250 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail",
"shortName": "Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": "4",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlipure",
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20210701_20210930",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100260 - Disclosure - Net Loss Per Common Share - Schedule of Outstanding Options Excluded from Computation of Diluted Income (Loss) Per Share (Detail)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingOptionsExcludedFromComputationOfDilutedIncomeLossPerShareDetail",
"shortName": "Net Loss Per Common Share - Schedule of Outstanding Options Excluded from Computation of Diluted Income (Loss) Per Share (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20210701_20210930",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210701_20210930",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:RestructuringCharges",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100270 - Disclosure - Restructuring Activities - Additional Information (Detail)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail",
"shortName": "Restructuring Activities - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_srtRangeAxis_srtMaximumMember_20200701_20200930",
"decimals": "-5",
"lang": null,
"name": "us-gaap:PaymentsForRestructuring",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
"us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20191231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RestructuringReserveCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100280 - Disclosure - Restructuring Activities - Summary of Charges Related to Restructuring Activities (Detail)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesSummaryOfChargesRelatedToRestructuringActivitiesDetail",
"shortName": "Restructuring Activities - Summary of Charges Related to Restructuring Activities (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
"us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20191231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RestructuringReserveCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210930",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD_xbrlishares",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
"shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210930",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD_xbrlishares",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210701_20210930",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:GeneralAndAdministrativeExpense",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
"shortName": "Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210701_20210930",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:GeneralAndAdministrativeExpense",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20191231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:StockholdersEquity",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
"shortName": "Condensed Consolidated Statements of Stockholders' Equity",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20200101_20200331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ProfitLoss",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100050 - Statement - Condensed Consolidated Statements of Cash Flows",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"shortName": "Condensed Consolidated Statements of Cash Flows",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": "-3",
"lang": null,
"name": "mack:GainOnSaleOfInProcessResearchAndDevelopmentAsset",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NatureOfOperations",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100060 - Disclosure - Nature of the Business",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusiness",
"shortName": "Nature of the Business",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NatureOfOperations",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100070 - Disclosure - Summary of Significant Accounting Policies",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
"shortName": "Summary of Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100080 - Disclosure - Fair Value of Financial Instruments",
"role": "http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstruments",
"shortName": "Fair Value of Financial Instruments",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "mack-10q_20210930.htm",
"contextRef": "C_0001274792_20210101_20210930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 24,
"tag": {
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus",
"terseLabel": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus",
"terseLabel": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r280"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report",
"terseLabel": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r281"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report",
"terseLabel": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"verboseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address Address Line1",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine2": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 2 such as Street or Suite number",
"label": "Entity Address Address Line2",
"terseLabel": "Entity Address, Address Line Two"
}
}
},
"localname": "EntityAddressAddressLine2",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address City Or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address State Or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r282"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock Shares Outstanding",
"terseLabel": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status",
"terseLabel": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
"label": "Entity [Domain]",
"terseLabel": "Entity"
}
}
},
"localname": "EntityDomain",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r282"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r282"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category",
"terseLabel": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation State Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r283"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current",
"terseLabel": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r282"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r282"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company",
"terseLabel": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r282"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business",
"terseLabel": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r282"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "employerIdItemType"
},
"dei_LegalEntityAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The set of legal entities associated with a report.",
"label": "Legal Entity [Axis]",
"terseLabel": "Legal Entity"
}
}
},
"localname": "LegalEntityAxis",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r278"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Security12b Title",
"terseLabel": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r279"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name",
"terseLabel": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_TradingSymbol": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol",
"terseLabel": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "tradingSymbolItemType"
},
"mack_AccruedAndOtherLiabilities": {
"auth_ref": [],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail": {
"order": 10040.0,
"parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accrued and other liabilities.",
"label": "Accrued And Other Liabilities",
"terseLabel": "Others"
}
}
},
"localname": "AccruedAndOtherLiabilities",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail"
],
"xbrltype": "monetaryItemType"
},
"mack_AccruedClinicalTrialCosts": {
"auth_ref": [],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail": {
"order": 10030.0,
"parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred through that date arising from ongoing clinical trial activity.",
"label": "Accrued Clinical Trial Costs",
"verboseLabel": "Accrued clinical trial costs"
}
}
},
"localname": "AccruedClinicalTrialCosts",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail"
],
"xbrltype": "monetaryItemType"
},
"mack_AdditionalIndicationMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Additional Indication [Member]",
"terseLabel": "Additional Indication [Member]"
}
}
},
"localname": "AdditionalIndicationMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_AdditionalPaymentsReceivableOnAchievementOfCertainMilestoneEvents": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Additional payments receivable on achievement of certain milestone events.",
"label": "Additional Payments Receivable On Achievement Of Certain Milestone Events",
"terseLabel": "Additional payments receivable on achievement of certain milestone events"
}
}
},
"localname": "AdditionalPaymentsReceivableOnAchievementOfCertainMilestoneEvents",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"mack_AfterFailureOfFirstLineChemotherapyMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "After Failure Of First Line Chemotherapy [Member]",
"terseLabel": "After Failure of First Line Chemotherapy [Member]"
}
}
},
"localname": "AfterFailureOfFirstLineChemotherapyMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees": {
"auth_ref": [],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"order": 10090.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and nonemployees.",
"label": "Allocated Share Based Compensation Expense Including Non Employees",
"terseLabel": "Stock-based compensation expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpenseIncludingNonEmployees",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"mack_AssetPurchaseOptionAgreementMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Asset purchase option agreement.",
"label": "Asset Purchase Option Agreement [Member]",
"terseLabel": "Asset Purchase Option Agreement [Member]"
}
}
},
"localname": "AssetPurchaseOptionAgreementMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_AssetSaleAgreementMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Asset sale agreement.",
"label": "Asset Sale Agreement [Member]",
"terseLabel": "Asset Sale Agreement [Member]"
}
}
},
"localname": "AssetSaleAgreementMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_CashPaymentReceived": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Cash payment received.",
"label": "Cash Payment Received",
"terseLabel": "Cash payment received"
}
}
},
"localname": "CashPaymentReceived",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"mack_CelatorPharmaceuticalsIncMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Celator Pharmaceuticals Inc [Member].",
"label": "Celator Pharmaceuticals Inc [Member]",
"terseLabel": "Celator Pharmaceuticals Inc [Member]"
}
}
},
"localname": "CelatorPharmaceuticalsIncMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_ConsiderationReceivable": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Consideration receivable.",
"label": "Consideration Receivable",
"terseLabel": "Consideration receivable"
}
}
},
"localname": "ConsiderationReceivable",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"mack_ContingentMilestonePaymentsReceivable": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Contingent milestone payments receivable.",
"label": "Contingent Milestone Payments Receivable",
"terseLabel": "Contingent milestone payments receivable"
}
}
},
"localname": "ContingentMilestonePaymentsReceivable",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"mack_ExercisePeriodOfOption": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Exercise period of option.",
"label": "Exercise Period Of Option",
"terseLabel": "Exercise period of option"
}
}
},
"localname": "ExercisePeriodOfOption",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "durationItemType"
},
"mack_FirstLineTreatmentOfMetastaticAdenocarcinomaOfPancreasMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "First Line Treatment Of Metastatic Adenocarcinoma Of Pancreas [Member]",
"terseLabel": "First Line Treatment of Metastatic Adenocarcinoma of Pancreas [Member]"
}
}
},
"localname": "FirstLineTreatmentOfMetastaticAdenocarcinomaOfPancreasMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_FourteenerOncologyIncMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Fourteener oncology inc member.",
"label": "Fourteener Oncology Inc [Member]",
"terseLabel": "14ner Sale [Member]"
}
}
},
"localname": "FourteenerOncologyIncMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_GainLossOnPaymentOfOptionFee": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) on payment of option fee.",
"label": "Gain Loss On Payment Of Option Fee",
"terseLabel": "Gain related to option fee payment"
}
}
},
"localname": "GainLossOnPaymentOfOptionFee",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"mack_GainOnSaleOfInProcessResearchAndDevelopmentAsset": {
"auth_ref": [],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"order": 10080.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Gain on sale of in progress research and development asset.",
"label": "Gain On Sale Of In Process Research And Development Asset",
"negatedLabel": "Gain on sale of in process research and development"
}
}
},
"localname": "GainOnSaleOfInProcessResearchAndDevelopmentAsset",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"mack_IpsenSAMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Ipsen S.A.",
"label": "Ipsen S A [Member]",
"terseLabel": "Ipsen [Member]"
}
}
},
"localname": "IpsenSAMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_MilestoneAchievementOneMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Milestone achievement one member.",
"label": "Milestone Achievement One [Member]",
"terseLabel": "Achievement of the Primary Endpoint in the First Registrational Clinical Study of Either MM-121 or MM-111 [Member]"
}
}
},
"localname": "MilestoneAchievementOneMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_MilestoneAchievementThreeMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Milestone achievement three member.",
"label": "Milestone Achievement Three [Member]",
"terseLabel": "Achievement Various Cumulative Worldwide Net Sales Targets Between $100.0 million and $300.0 million for MM-121 and MM-111 [Member]"
}
}
},
"localname": "MilestoneAchievementThreeMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_MilestoneAchievementTwoMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Milestone achievement two member.",
"label": "Milestone Achievement Two [Member]",
"terseLabel": "Achievement of Various Regulatory Approval and Reimbursement-Based Milestones in the United States, Europe and Japan [Member]"
}
}
},
"localname": "MilestoneAchievementTwoMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_NetProceedsFromSaleOfInProgressResearchAndDevelopmentAsset": {
"auth_ref": [],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"order": 10060.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Net proceeds from sale of in progress research and development asset.",
"label": "Net Proceeds From Sale Of In Progress Research And Development Asset",
"terseLabel": "Net proceeds from sale of in process research and development"
}
}
},
"localname": "NetProceedsFromSaleOfInProgressResearchAndDevelopmentAsset",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"mack_NovemberTwoThousandEighteenCorporateRestructuringMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "November two thousand eighteen corporate restructuring.",
"label": "November Two Thousand Eighteen Corporate Restructuring [Member]",
"terseLabel": "November 2018 Corporate Restructuring [Member]"
}
}
},
"localname": "NovemberTwoThousandEighteenCorporateRestructuringMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_OptionFee": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Option fee.",
"label": "Option Fee",
"terseLabel": "Option fee"
}
}
},
"localname": "OptionFee",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"mack_PegascySASMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Pegascy SAS.",
"label": "Pegascy S A S [Member]",
"terseLabel": "Pegascy SAS [Member]"
}
}
},
"localname": "PegascySASMember",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_ReimbursementRevenues": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Repayment received or receivable for expenses incurred on behalf of a client or customer, other than those reimbursements received by landlords from tenants.",
"label": "Reimbursement Revenues",
"terseLabel": "Reimbursement of expenses"
}
}
},
"localname": "ReimbursementRevenues",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"mack_StockIncentivePlan2021Member": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Stock Incentive Plan 2021 [Member].",
"label": "Stock Incentive Plan2021 [Member]",
"terseLabel": "Stock Incentive Plan 2021 [Member]"
}
}
},
"localname": "StockIncentivePlan2021Member",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"mack_SummaryOfSignificantAccountingPoliciesLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Summary of significant accounting policies.",
"label": "Summary Of Significant Accounting Policies [Line Items]",
"terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
}
}
},
"localname": "SummaryOfSignificantAccountingPoliciesLineItems",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"mack_SummaryOfSignificantAccountingPoliciesTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Summary of significant accounting policies.",
"label": "Summary Of Significant Accounting Policies [Table]",
"terseLabel": "Summary Of Significant Accounting Policies [Table]"
}
}
},
"localname": "SummaryOfSignificantAccountingPoliciesTable",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"mack_TransactionExpenses": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Transaction expenses.",
"label": "Transaction Expenses",
"terseLabel": "Transaction expenses"
}
}
},
"localname": "TransactionExpenses",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"mack_UpfrontCashPaymentReceived": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Upfront cash payment received.",
"label": "Upfront Cash Payment Received",
"terseLabel": "Upfront cash payment received"
}
}
},
"localname": "UpfrontCashPaymentReceived",
"nsuri": "http://www.merrimackpharma.com/20210930",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"srt_CounterpartyNameAxis": {
"auth_ref": [
"r28",
"r30",
"r58",
"r59",
"r148",
"r154"
],
"lang": {
"en-us": {
"role": {
"label": "Counterparty Name [Axis]",
"terseLabel": "Counterparty Name"
}
}
},
"localname": "CounterpartyNameAxis",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"srt_MaximumMember": {
"auth_ref": [
"r147",
"r153",
"r172",
"r174",
"r245",
"r246",
"r247",
"r248",
"r249",
"r250",
"r251",
"r266",
"r267",
"r276",
"r277"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum [Member]",
"terseLabel": "Maximum [Member]"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_MinimumMember": {
"auth_ref": [
"r147",
"r153",
"r172",
"r174",
"r245",
"r246",
"r247",
"r248",
"r249",
"r250",
"r251",
"r266",
"r267",
"r276",
"r277"
],
"lang": {
"en-us": {
"role": {
"label": "Minimum [Member]",
"terseLabel": "Minimum [Member]"
}
}
},
"localname": "MinimumMember",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
"r147",
"r153",
"r163",
"r172",
"r174",
"r245",
"r246",
"r247",
"r248",
"r249",
"r250",
"r251",
"r266",
"r267",
"r276",
"r277"
],
"lang": {
"en-us": {
"role": {
"label": "Range [Axis]",
"terseLabel": "Statistical Measurement"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
"r147",
"r153",
"r163",
"r172",
"r174",
"r245",
"r246",
"r247",
"r248",
"r249",
"r250",
"r251",
"r266",
"r267",
"r276",
"r277"
],
"lang": {
"en-us": {
"role": {
"label": "Range [Member]",
"terseLabel": "Statistical Measurement"
}
}
},
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_RepurchaseAgreementCounterpartyNameDomain": {
"auth_ref": [
"r29",
"r30",
"r58",
"r59",
"r148",
"r154"
],
"lang": {
"en-us": {
"role": {
"label": "Repurchase Agreement Counterparty Name [Domain]",
"terseLabel": "Counterparty Name"
}
}
},
"localname": "RepurchaseAgreementCounterpartyNameDomain",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_ScenarioUnspecifiedDomain": {
"auth_ref": [
"r70",
"r74",
"r173"
],
"lang": {
"en-us": {
"role": {
"label": "Scenario Unspecified [Domain]",
"terseLabel": "Scenario"
}
}
},
"localname": "ScenarioUnspecifiedDomain",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_StatementScenarioAxis": {
"auth_ref": [
"r70",
"r74",
"r135",
"r173",
"r241"
],
"lang": {
"en-us": {
"role": {
"label": "Statement Scenario [Axis]",
"terseLabel": "Scenario"
}
}
},
"localname": "StatementScenarioAxis",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Accounting Changes And Error Corrections [Abstract]"
}
}
},
"localname": "AccountingChangesAndErrorCorrectionsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
"auth_ref": [
"r21"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10090.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
"label": "Accounts Payable And Accrued Liabilities Current",
"terseLabel": "Accounts payable, accrued expenses and other",
"totalLabel": "Total accounts payable, accrued expenses and other"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
"auth_ref": [
"r20"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
"label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
"terseLabel": "Accounts Payable, Accrued Expenses and Other"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r19",
"r240"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail": {
"order": 10010.0,
"parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable Current",
"terseLabel": "Accounts payable"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedLiabilitiesCurrent": {
"auth_ref": [
"r23"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail": {
"order": 10020.0,
"parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Liabilities Current",
"terseLabel": "Accrued goods and services"
}
}
},
"localname": "AccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalCommonStock": {
"auth_ref": [
"r10"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10060.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
"label": "Additional Paid In Capital Common Stock",
"terseLabel": "Additional paid-in capital"
}
}
},
"localname": "AdditionalPaidInCapitalCommonStock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r61",
"r62",
"r63",
"r187",
"r188",
"r189",
"r213"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid In Capital [Member]",
"terseLabel": "Additional Paid-In Capital [Member]"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
"auth_ref": [
"r175",
"r176",
"r194",
"r195"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
"label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
"terseLabel": "Stock-based compensation"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"auth_ref": [
"r176",
"r184",
"r193"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
"label": "Allocated Share Based Compensation Expense",
"terseLabel": "Allocated Share Based Compensation Expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r78"
],
"lang": {
"en-us": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
"terseLabel": "Outstanding options to purchase common stock"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingOptionsExcludedFromComputationOfDilutedIncomeLossPerShareDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
"auth_ref": [
"r78"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of antidilutive security.",
"label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
"terseLabel": "Antidilutive Securities"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingOptionsExcludedFromComputationOfDilutedIncomeLossPerShareDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
"terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingOptionsExcludedFromComputationOfDilutedIncomeLossPerShareDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesNameDomain": {
"auth_ref": [
"r78"
],
"lang": {
"en-us": {
"role": {
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
"label": "Antidilutive Securities Name [Domain]",
"terseLabel": "Antidilutive Securities, Name"
}
}
},
"localname": "AntidilutiveSecuritiesNameDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingOptionsExcludedFromComputationOfDilutedIncomeLossPerShareDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Arrangements And Nonarrangement Transactions [Member]",
"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
}
}
},
"localname": "ArrangementsAndNonarrangementTransactionsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r57",
"r95",
"r98",
"r104",
"r112",
"r136",
"r137",
"r138",
"r139",
"r140",
"r141",
"r142",
"r143",
"r144",
"r145",
"r146",
"r204",
"r208",
"r226",
"r238",
"r240",
"r256",
"r261"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "Assets"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r5",
"r6",
"r27",
"r57",
"r112",
"r136",
"r137",
"r138",
"r139",
"r140",
"r141",
"r142",
"r143",
"r144",
"r145",
"r146",
"r204",
"r208",
"r226",
"r238",
"r240"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10100.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Assets Current [Abstract]",
"terseLabel": "Current assets:"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Basis Of Accounting Policy Policy [Text Block]",
"terseLabel": "Basis of Presentation"
}
}
},
"localname": "BasisOfAccountingPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r4",
"r17",
"r54"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10120.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash And Cash Equivalents At Carrying Value",
"terseLabel": "Cash and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash And Cash Equivalents Fair Value Disclosure",
"terseLabel": "Cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsAndShortTermInvestments": {
"auth_ref": [
"r17"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
"label": "Cash Cash Equivalents And Short Term Investments",
"terseLabel": "Cash, cash equivalents and marketable securities"
}
}
},
"localname": "CashCashEquivalentsAndShortTermInvestments",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r49",
"r54",
"r55"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
"periodEndLabel": "Cash and cash equivalents, end of period",
"periodStartLabel": "Cash and cash equivalents, beginning of period"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r49",
"r230"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
"totalLabel": "Net increase (decrease) in cash and cash equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r25",
"r134",
"r258",
"r264"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10020.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "Commitments And Contingencies",
"terseLabel": "Commitments and contingencies"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r61",
"r62",
"r213"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "Common Stock [Member]"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r9"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock Par Or Stated Value Per Share",
"terseLabel": "Common stock, par value"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r9"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock Shares Authorized",
"terseLabel": "Common stock, shares authorized"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r9"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock Shares Issued",
"terseLabel": "Common stock, shares issued"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r9",
"r155"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common Stock Shares Outstanding",
"terseLabel": "Common stock, shares outstanding"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r9",
"r240"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10050.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common Stock Value",
"terseLabel": "Common stock, $0.01 par value: 30,000 shares authorized at September 30, 2021 and December 31, 2020; 13,410 and 13,380 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComparabilityOfPriorYearFinancialData": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for reporting any exceptions to the comparability of prior year financial data with data shown for the most recent accounting period.",
"label": "Comparability Of Prior Year Financial Data",
"terseLabel": "Unaudited Interim Financial Information"
}
}
},
"localname": "ComparabilityOfPriorYearFinancialData",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTax": {
"auth_ref": [
"r32",
"r34",
"r35",
"r39",
"r259",
"r265"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income Net Of Tax",
"negatedLabel": "Net loss from continuing operations",
"totalLabel": "Net loss and comprehensive loss"
}
}
},
"localname": "ComprehensiveIncomeNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
"auth_ref": [
"r196"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for share-based payment arrangement.",
"label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
"terseLabel": "Stock-Based Compensation"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share [Abstract]"
}
}
},
"localname": "EarningsPerShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasicAndDiluted": {
"auth_ref": [
"r77"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share Basic And Diluted",
"terseLabel": "Net loss per common share - basic and diluted"
}
}
},
"localname": "EarningsPerShareBasicAndDiluted",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareTextBlock": {
"auth_ref": [
"r78",
"r79",
"r80",
"r81"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for earnings per share.",
"label": "Earnings Per Share [Text Block]",
"terseLabel": "Net Loss Per Common Share"
}
}
},
"localname": "EarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShare"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EmployeeSeveranceMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
"label": "Employee Severance [Member]",
"terseLabel": "Severance, Benefits and Related Costs Due to Workforce Reduction [Member]"
}
}
},
"localname": "EmployeeSeveranceMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesSummaryOfChargesRelatedToRestructuringActivitiesDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r0",
"r36",
"r37",
"r38",
"r61",
"r62",
"r63",
"r67",
"r71",
"r73",
"r82",
"r113",
"r155",
"r156",
"r187",
"r188",
"r189",
"r197",
"r198",
"r213",
"r231",
"r232",
"r233",
"r234",
"r235",
"r236",
"r268",
"r269",
"r270",
"r284"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]",
"terseLabel": "Equity Component"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
"terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
"auth_ref": [
"r215",
"r216",
"r217",
"r222"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
"label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
"terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
"auth_ref": [
"r215",
"r216"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Fair Value Assets Measured On Recurring Basis [Text Block]",
"terseLabel": "Summary of Assets Measured at Fair Value on a Recurring Basis"
}
}
},
"localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
"auth_ref": [
"r220"
],
"lang": {
"en-us": {
"role": {
"documentation": "Class of asset.",
"label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
"terseLabel": "Asset Class"
}
}
},
"localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
"terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]"
}
}
},
"localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByAssetClassAxis": {
"auth_ref": [
"r215",
"r222"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by class of asset.",
"label": "Fair Value By Asset Class [Axis]",
"terseLabel": "Asset Class"
}
}
},
"localname": "FairValueByAssetClassAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByBalanceSheetGroupingTable": {
"auth_ref": [
"r215",
"r224",
"r225"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
"label": "Fair Value By Balance Sheet Grouping [Table]",
"terseLabel": "Fair Value By Balance Sheet Grouping [Table]"
}
}
},
"localname": "FairValueByBalanceSheetGroupingTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r149",
"r150",
"r151",
"r164",
"r165",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r216",
"r242",
"r243",
"r244"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value By Fair Value Hierarchy Level [Axis]",
"terseLabel": "Level 2 [Member]"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByMeasurementFrequencyAxis": {
"auth_ref": [
"r215",
"r216",
"r218",
"r219",
"r223"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by measurement frequency.",
"label": "Fair Value By Measurement Frequency [Axis]",
"terseLabel": "Measurement Frequency"
}
}
},
"localname": "FairValueByMeasurementFrequencyAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Disclosures [Abstract]"
}
}
},
"localname": "FairValueDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresTextBlock": {
"auth_ref": [
"r221"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
"label": "Fair Value Disclosures [Text Block]",
"terseLabel": "Fair Value of Financial Instruments"
}
}
},
"localname": "FairValueDisclosuresTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstruments"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r149",
"r164",
"r165",
"r170",
"r171",
"r216",
"r242"
],
"lang": {
"en-us": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Fair Value Inputs Level1 [Member]",
"terseLabel": "Level 1 [Member]"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r149",
"r150",
"r151",
"r164",
"r165",
"r170",
"r171",
"r216",
"r243"
],
"lang": {
"en-us": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Fair Value Inputs Level2 [Member]",
"terseLabel": "Level 2 [Member]"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel3Member": {
"auth_ref": [
"r149",
"r150",
"r151",
"r164",
"r165",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r216",
"r244"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value Inputs Level3 [Member]",
"terseLabel": "Level 3 [Member]"
}
}
},
"localname": "FairValueInputsLevel3Member",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementFrequencyDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Measurement frequency.",
"label": "Fair Value Measurement Frequency [Domain]",
"terseLabel": "Measurement Frequency"
}
}
},
"localname": "FairValueMeasurementFrequencyDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
"r149",
"r150",
"r151",
"r164",
"r165",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r242",
"r243",
"r244"
],
"lang": {
"en-us": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
"terseLabel": "Fair Value Hierarchy and NAV"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsRecurringMember": {
"auth_ref": [
"r221",
"r223"
],
"lang": {
"en-us": {
"role": {
"documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
"label": "Fair Value Measurements Recurring [Member]",
"terseLabel": "Recurring Basis [Member]"
}
}
},
"localname": "FairValueMeasurementsRecurringMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_GainLossOnDispositionOfAssets1": {
"auth_ref": [
"r52"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
"order": 10070.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
"label": "Gain Loss On Disposition Of Assets1",
"negatedLabel": "Gain on sale of assets"
}
}
},
"localname": "GainLossOnDispositionOfAssets1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpense": {
"auth_ref": [
"r41"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
"order": 10060.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
"label": "General And Administrative Expense",
"terseLabel": "General and administrative expenses"
}
}
},
"localname": "GeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpenseMember": {
"auth_ref": [
"r40"
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing general and administrative expense.",
"label": "General And Administrative Expense [Member]",
"terseLabel": "General and Administrative Expense [Member]"
}
}
},
"localname": "GeneralAndAdministrativeExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r116",
"r121"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]",
"terseLabel": "Income Statement Location"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
"r121"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the income statement.",
"label": "Income Statement Location [Domain]",
"terseLabel": "Income Statement Location"
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
"auth_ref": [
"r51"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"order": 10110.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
"label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
"terseLabel": "Accounts payable, accrued expenses and other"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Increase Decrease In Operating Capital [Abstract]",
"terseLabel": "Changes in operating assets and liabilities:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"auth_ref": [
"r51"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"order": 10100.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
"label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
"negatedLabel": "Prepaid expenses and other assets"
}
}
},
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentIncomeInterest": {
"auth_ref": [
"r42",
"r94"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
"order": 10030.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
"label": "Investment Income Interest",
"terseLabel": "Interest income"
}
}
},
"localname": "InvestmentIncomeInterest",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r22",
"r57",
"r99",
"r112",
"r136",
"r137",
"r138",
"r140",
"r141",
"r142",
"r143",
"r144",
"r145",
"r146",
"r205",
"r208",
"r209",
"r226",
"r238",
"r239"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10010.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "Liabilities",
"totalLabel": "Total liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r14",
"r57",
"r112",
"r226",
"r240",
"r257",
"r263"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities And Stockholders Equity",
"totalLabel": "Total liabilities and stockholders\u2019 equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Liabilities And Stockholders Equity [Abstract]",
"terseLabel": "Liabilities and stockholders\u2019 equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r24",
"r57",
"r112",
"r136",
"r137",
"r138",
"r140",
"r141",
"r142",
"r143",
"r144",
"r145",
"r146",
"r205",
"r208",
"r209",
"r226",
"r238",
"r239",
"r240"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10080.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Liabilities Current [Abstract]",
"terseLabel": "Current liabilities:"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesFairValueDisclosure": {
"auth_ref": [
"r215"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of financial and nonfinancial obligations.",
"label": "Liabilities Fair Value Disclosure",
"terseLabel": "Liabilities measured at fair value"
}
}
},
"localname": "LiabilitiesFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MoneyMarketFundsMember": {
"auth_ref": [
"r164"
],
"lang": {
"en-us": {
"role": {
"documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
"label": "Money Market Funds [Member]",
"terseLabel": "Money Market Funds [Member]"
}
}
},
"localname": "MoneyMarketFundsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_NatureOfOperations": {
"auth_ref": [
"r83",
"r91"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
"label": "Nature Of Operations",
"terseLabel": "Nature of the Business"
}
}
},
"localname": "NatureOfOperations",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusiness"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r49"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"order": 10030.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided By Used In Financing Activities",
"totalLabel": "Net cash provided by (used in) financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided By Used In Financing Activities [Abstract]",
"terseLabel": "Cash flows from financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r49"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"order": 10020.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided By Used In Investing Activities",
"totalLabel": "Net cash provided by investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided By Used In Investing Activities [Abstract]",
"terseLabel": "Cash flows from investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r49",
"r50",
"r53"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"order": 10010.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided By Used In Operating Activities",
"terseLabel": "Cash used in operating activities",
"totalLabel": "Net cash provided by (used in) operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided By Used In Operating Activities [Abstract]",
"terseLabel": "Cash flows from operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
"auth_ref": [
"r1",
"r64",
"r65",
"r68",
"r69",
"r74",
"r75",
"r76",
"r110",
"r111",
"r114",
"r115",
"r159",
"r160",
"r161",
"r162",
"r190",
"r199",
"r200",
"r201",
"r212",
"r227",
"r228",
"r229",
"r237",
"r253",
"r254",
"r255",
"r271",
"r272",
"r273",
"r274",
"r275",
"r285"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
"label": "New Accounting Pronouncements And Changes In Accounting Principles [Text Block]",
"terseLabel": "Recent Accounting Pronouncements"
}
}
},
"localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRecentAccountingPronouncements"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements Policy Policy [Text Block]",
"terseLabel": "Recent Accounting Pronouncements"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NonoperatingIncomeExpense": {
"auth_ref": [
"r43"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
"order": 10020.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
"label": "Nonoperating Income Expense",
"totalLabel": "Total other income"
}
}
},
"localname": "NonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NonoperatingIncomeExpenseAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Nonoperating Income Expense [Abstract]",
"terseLabel": "Other income:"
}
}
},
"localname": "NonoperatingIncomeExpenseAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingExpenses": {
"auth_ref": [],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
"order": 10050.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
"label": "Operating Expenses",
"totalLabel": "Total operating expenses"
}
}
},
"localname": "OperatingExpenses",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingExpensesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Operating Expenses [Abstract]",
"terseLabel": "Operating expenses:"
}
}
},
"localname": "OperatingExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r95",
"r97",
"r100",
"r103",
"r105"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
"order": 10010.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income Loss",
"totalLabel": "Loss from operations"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_OtherAssetsNoncurrent": {
"auth_ref": [
"r18"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10110.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncurrent assets classified as other.",
"label": "Other Assets Noncurrent",
"terseLabel": "Other assets"
}
}
},
"localname": "OtherAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r44"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
"order": 10040.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income Expense",
"terseLabel": "Other income, net"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PayablesAndAccrualsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Payables And Accruals [Abstract]"
}
}
},
"localname": "PayablesAndAccrualsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_PaymentsForRestructuring": {
"auth_ref": [
"r47",
"r120"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
"label": "Payments For Restructuring",
"negatedLabel": "Less: Payments",
"terseLabel": "Payments for restructuring"
}
}
},
"localname": "PaymentsForRestructuring",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesSummaryOfChargesRelatedToRestructuringActivitiesDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PlanNameAxis": {
"auth_ref": [
"r177",
"r185"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by plan name for share-based payment arrangement.",
"label": "Plan Name [Axis]",
"terseLabel": "Plan Name"
}
}
},
"localname": "PlanNameAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_PlanNameDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Plan name for share-based payment arrangement.",
"label": "Plan Name [Domain]",
"terseLabel": "Plan Name"
}
}
},
"localname": "PlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"auth_ref": [
"r8",
"r152"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
"label": "Preferred Stock Par Or Stated Value Per Share",
"terseLabel": "Preferred stock, par value"
}
}
},
"localname": "PreferredStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r8"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred Stock Shares Authorized",
"terseLabel": "Preferred stock, shares authorized"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r8",
"r152"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred Stock Shares Issued",
"terseLabel": "Preferred stock, shares issued"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r8"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Preferred Stock Shares Outstanding",
"terseLabel": "Preferred stock, shares outstanding"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValue": {
"auth_ref": [
"r8",
"r240"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10040.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Preferred Stock Value",
"terseLabel": "Preferred stock, $0.01 par value: 10,000 shares authorized at September 30, 2021 and December 31, 2020; no shares issued or outstanding at September 30, 2021 or December 31, 2020"
}
}
},
"localname": "PreferredStockValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
"auth_ref": [
"r5",
"r15",
"r16"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10130.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
"label": "Prepaid Expense And Other Assets Current",
"terseLabel": "Prepaid expenses and other current assets"
}
}
},
"localname": "PrepaidExpenseAndOtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromStockOptionsExercised": {
"auth_ref": [
"r45",
"r186"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"order": 10040.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
"label": "Proceeds From Stock Options Exercised",
"terseLabel": "Proceeds from exercise of stock options"
}
}
},
"localname": "ProceedsFromStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProfitLoss": {
"auth_ref": [
"r3",
"r31",
"r33",
"r38",
"r48",
"r57",
"r66",
"r72",
"r73",
"r95",
"r97",
"r100",
"r103",
"r105",
"r112",
"r136",
"r137",
"r138",
"r140",
"r141",
"r142",
"r143",
"r144",
"r145",
"r146",
"r203",
"r206",
"r207",
"r210",
"r211",
"r214",
"r226",
"r260"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"order": 10070.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
"label": "Profit Loss",
"terseLabel": "Net income (loss)"
}
}
},
"localname": "ProfitLoss",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RepaymentsOfLongTermDebt": {
"auth_ref": [
"r46"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"order": 10050.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
"label": "Repayments Of Long Term Debt",
"negatedLabel": "Repayment of debt"
}
}
},
"localname": "RepaymentsOfLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringAndRelatedActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Restructuring And Related Activities [Abstract]"
}
}
},
"localname": "RestructuringAndRelatedActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
"auth_ref": [
"r118",
"r120",
"r123",
"r132",
"r133"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
"label": "Restructuring And Related Activities Disclosure [Text Block]",
"terseLabel": "Restructuring Activities"
}
}
},
"localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivities"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RestructuringAndRelatedActivitiesInitiationDate": {
"auth_ref": [
"r118",
"r128"
],
"lang": {
"en-us": {
"role": {
"documentation": "Date the restructuring activities were initiated or are expected to be initiated, in YYYY-MM-DD format.",
"label": "Restructuring And Related Activities Initiation Date",
"terseLabel": "Restructuring activity, announcement date"
}
}
},
"localname": "RestructuringAndRelatedActivitiesInitiationDate",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail"
],
"xbrltype": "dateItemType"
},
"us-gaap_RestructuringCharges": {
"auth_ref": [
"r52",
"r117",
"r126",
"r129"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
"label": "Restructuring Charges",
"terseLabel": "Restructuring expenses",
"verboseLabel": "Expenses"
}
}
},
"localname": "RestructuringCharges",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesSummaryOfChargesRelatedToRestructuringActivitiesDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringCostAndReserveAxis": {
"auth_ref": [
"r119",
"r120",
"r129",
"r130"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of restructuring cost.",
"label": "Restructuring Cost And Reserve [Axis]",
"terseLabel": "Restructuring Type"
}
}
},
"localname": "RestructuringCostAndReserveAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesSummaryOfChargesRelatedToRestructuringActivitiesDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringCostAndReserveLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Restructuring Cost And Reserve [Line Items]",
"terseLabel": "Restructuring Cost And Reserve [Line Items]"
}
}
},
"localname": "RestructuringCostAndReserveLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesSummaryOfChargesRelatedToRestructuringActivitiesDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringPlanAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Information by individual restructuring plan.",
"label": "Restructuring Plan [Axis]",
"terseLabel": "Restructuring Plan"
}
}
},
"localname": "RestructuringPlanAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringPlanDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the individual restructuring plans.",
"label": "Restructuring Plan [Domain]",
"terseLabel": "Restructuring Plan"
}
}
},
"localname": "RestructuringPlanDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestructuringReserveCurrent": {
"auth_ref": [
"r7",
"r120",
"r130"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.",
"label": "Restructuring Reserve Current",
"periodEndLabel": "Accrued Restructuring Expenses",
"periodStartLabel": "Accrued Restructuring Expenses"
}
}
},
"localname": "RestructuringReserveCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesSummaryOfChargesRelatedToRestructuringActivitiesDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringReserveSettledWithoutCash2": {
"auth_ref": [
"r120",
"r130"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
"label": "Restructuring Reserve Settled Without Cash2",
"negatedLabel": "Less: Non-Cash Expenses"
}
}
},
"localname": "RestructuringReserveSettledWithoutCash2",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesSummaryOfChargesRelatedToRestructuringActivitiesDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r11",
"r156",
"r191",
"r240",
"r262",
"r271",
"r275"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10070.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings Accumulated Deficit",
"negatedLabel": "Accumulated deficit",
"terseLabel": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r0",
"r61",
"r62",
"r63",
"r67",
"r71",
"r73",
"r113",
"r187",
"r188",
"r189",
"r197",
"r198",
"r213",
"r268",
"r270"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]",
"terseLabel": "Accumulated Deficit [Member]"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
"auth_ref": [
"r92",
"r93",
"r96",
"r101",
"r102",
"r106",
"r107",
"r108",
"r157",
"r158",
"r252"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
"label": "Revenue From Contract With Customer Including Assessed Tax",
"terseLabel": "Cumulative worldwide net sales target"
}
}
},
"localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
"label": "Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]",
"terseLabel": "Schedule of Accounts Payable, Accrued Expenses and Other"
}
}
},
"localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
"auth_ref": [
"r78"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
"label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
"terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingOptionsExcludedFromComputationOfDilutedIncomeLossPerShareDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
"auth_ref": [
"r78"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
"label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
"terseLabel": "Schedule of Outstanding Options Excluded from Computation of Diluted Loss Per Share"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShareTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
"auth_ref": [
"r119",
"r120",
"r121",
"r122",
"r129",
"r130",
"r131"
],
"lang": {
"en-us": {
"role": {
"documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
"label": "Schedule Of Restructuring And Related Costs [Table]",
"terseLabel": "Schedule Of Restructuring And Related Costs [Table]"
}
}
},
"localname": "ScheduleOfRestructuringAndRelatedCostsTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetail",
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesSummaryOfChargesRelatedToRestructuringActivitiesDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
"auth_ref": [
"r124",
"r125",
"r127"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
"label": "Schedule Of Restructuring And Related Costs [Text Block]",
"terseLabel": "Summary of Charges Related to Restructuring Activities"
}
}
},
"localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
"auth_ref": [
"r177",
"r185"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about share-based payment arrangement.",
"label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
"terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
"auth_ref": [
"r179"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
"label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
"terseLabel": "Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees"
}
}
},
"localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
"auth_ref": [
"r182"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
"terseLabel": "Expected dividend yield"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
"auth_ref": [
"r181"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
"terseLabel": "Expected volatility"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
"auth_ref": [
"r183"
],
"lang": {
"en-us": {
"role": {
"documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
"terseLabel": "Risk-free interest rate"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
"auth_ref": [
"r185"
],
"lang": {
"en-us": {
"role": {
"documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
"terseLabel": "Shares of common stock available for grant (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Gross number of share options (or share units) granted during the period.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
"terseLabel": "Number of Options, Granted"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
"label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
"terseLabel": "Weighted Average Exercise Price"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
"auth_ref": [
"r180",
"r192"
],
"lang": {
"en-us": {
"role": {
"documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
"terseLabel": "Expected term"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharesOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
"label": "Shares Outstanding",
"periodEndLabel": "Balance (in shares)",
"periodStartLabel": "Balance (in shares)"
}
}
},
"localname": "SharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "sharesItemType"
},
"us-gaap_SignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r56",
"r60"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
"label": "Significant Accounting Policies [Text Block]",
"terseLabel": "Summary of Significant Accounting Policies"
}
}
},
"localname": "SignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r0",
"r26",
"r36",
"r37",
"r38",
"r61",
"r62",
"r63",
"r67",
"r71",
"r73",
"r82",
"r113",
"r155",
"r156",
"r187",
"r188",
"r189",
"r197",
"r198",
"r213",
"r231",
"r232",
"r233",
"r234",
"r235",
"r236",
"r268",
"r269",
"r270",
"r284"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Statement Equity Components [Axis]",
"terseLabel": "Equity Components"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]",
"terseLabel": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement Of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement Of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement Of Income And Comprehensive Income [Abstract]"
}
}
},
"localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement Of Stockholders Equity [Abstract]"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r61",
"r62",
"r63",
"r82",
"r252"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]",
"terseLabel": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockCompensationPlanMember": {
"auth_ref": [
"r78"
],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
"label": "Stock Compensation Plan [Member]",
"terseLabel": "Outstanding Options to Purchase Common Stock [Member]"
}
}
},
"localname": "StockCompensationPlanMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfOutstandingOptionsExcludedFromComputationOfDilutedIncomeLossPerShareDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
"auth_ref": [
"r8",
"r9",
"r155",
"r156",
"r178"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of share options (or share units) exercised during the current period.",
"label": "Stock Issued During Period Shares Stock Options Exercised",
"terseLabel": "Exercise of stock options (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
"auth_ref": [
"r26",
"r155",
"r156"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of stock issued as a result of the exercise of stock options.",
"label": "Stock Issued During Period Value Stock Options Exercised",
"terseLabel": "Exercise of stock options"
}
}
},
"localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r9",
"r12",
"r13",
"r57",
"r109",
"r112",
"r226",
"r240"
],
"calculation": {
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 10030.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "Stockholders Equity",
"periodEndLabel": "Balance",
"periodStartLabel": "Balance",
"totalLabel": "Total stockholders\u2019 equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Stockholders Equity [Abstract]",
"terseLabel": "Stockholders\u2019 equity:"
}
}
},
"localname": "StockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_TypeOfArrangementAxis": {
"auth_ref": [
"r202"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Type Of Arrangement [Axis]",
"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
}
}
},
"localname": "TypeOfArrangementAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_TypeOfRestructuringDomain": {
"auth_ref": [
"r119",
"r120",
"r129",
"r130"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the types of restructuring costs.",
"label": "Type Of Restructuring [Domain]",
"terseLabel": "Type of Restructuring"
}
}
},
"localname": "TypeOfRestructuringDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureRestructuringActivitiesSummaryOfChargesRelatedToRestructuringActivitiesDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_UseOfEstimates": {
"auth_ref": [
"r84",
"r85",
"r86",
"r87",
"r88",
"r89",
"r90"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
"label": "Use Of Estimates",
"terseLabel": "Use of Estimates"
}
}
},
"localname": "UseOfEstimates",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
"label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
"terseLabel": "Weighted-average common shares used to compute basic and diluted net loss per common share"
}
}
},
"localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.merrimackpharma.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
],
"xbrltype": "sharesItemType"
}
},
"unitCount": 4
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "105",
"URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(d)(1)",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(d)(2)",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(1)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 5.P.3)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.3)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 5.P.4)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(a))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(b)(1))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(b)(2))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(d))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(e))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r133": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "420",
"URI": "http://asc.fasb.org/topic&trid=2175745"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(7))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(g)(2)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(8))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(i)(2)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(j)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(i)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(A)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(B)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(C)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.1)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(03)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(d)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(f)(3)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "80",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.17)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(i)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(ii)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iii)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iv)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(i)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "2A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(g)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(g)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 14.D.2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 14.F)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
},
"r196": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "718",
"URI": "http://asc.fasb.org/topic&trid=2228938"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=124429468&loc=d3e288-107754"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a),20,24)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(3)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "808",
"URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19,20)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "4J",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "4K",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(1)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(1)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(2)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(3)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "848",
"URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "855",
"URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "910",
"URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(f)(1)",
"Topic": "926",
"URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(f)(2)",
"Topic": "926",
"URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(f)(3)",
"Topic": "926",
"URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(26))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.(a),19)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(22))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "7A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "29F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.9)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(ii)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(iii)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(iv)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(c)",
"Topic": "976",
"URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "978",
"URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
},
"r278": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r279": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
},
"r280": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a"
},
"r281": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r282": {
"Name": "Regulation 12B",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r283": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "848"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(24))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(4))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7(b))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(m)(1)(iii))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(m)(2)(ii))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
},
"r60": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "http://asc.fasb.org/topic&trid=2122369"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(1)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(4)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.M.Q2)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
},
"r76": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "250",
"URI": "http://asc.fasb.org/topic&trid=2122394"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
},
"r81": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "260",
"URI": "http://asc.fasb.org/topic&trid=2144383"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
},
"r91": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "275",
"URI": "http://asc.fasb.org/topic&trid=2134479"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
}
},
"version": "2.1"
}
ZIP
48
0001564590-21-054518-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001564590-21-054518-xbrl.zip
M4$L#!!0 ( .*#9%/]TNN#R[4 "C;#@ 5 ;6%C:RTQ,'%?,C R,3 Y
M,S N:'1M[+UY=]M(LB_X]\PY\QURU%U][3,437 1);GL=V@M5;IE+2W)U;?G
M'Y\4D!31!@$6%LE\G_Y%) 27$6"()D HM^[91$$@Q&N9SKVIP.M6CM@PM8=P[2?/QT$?O?P^.!_??Y__N]?_]_#0W9^>77#.KIO
MOHAST],MQPM<\>[A^CV[LBW3%NQ_OMQ_9>>.'O2%[;-#UO/]P>F'#Z^OKU6C
M:]J>8P4^O,>KZD[_ SL\C!]\Y@J.7[!S[@LF_W?*ZK6Z=JAIA[7FH]8XK6NG
MS7JUW6P=U5K-_Z]6.ZW5$@_X,YP 2_SOE+6JM:I6;=?JB1OON/Z#/PMV=9ZX
M\/:H;W;9NG CQE!RI,QBZYG//9^_T]W*(,%_;
M%I8EANS2M+FMF]QB#_%,*[ T>I5U+(O=X\\\=B\\X;X(HQH]M><#!8 *MG?Z
M\\FUS$\'B57#*U7'??Y0K]4:'V %?7B!.$C<;XQ_D+SYZ$/X97QK'^8]\>2^
M<%T3KPYZW.US21&<3NVD48M_%'B'_G @O-$/N]Q[DF^(OY$_.:QIAPTM\:-G
MS@=S?X-?S/F)YP_?^8-ZMIKY@
M+*8^,12;F[HW_U;YU<3-XJ?>FW\O?C-QJ^&[4U.;Q9K\&6%[YI,E
M#O$VX4KI]P[KU1'O_02%,LFQKPWY .WDY.2#_';$<;Z[4&A./L"W\8TSCYP4
M+_SZB7LC\3(]IUG7VLL$,KQC-&;/G#=BN%7[\#_77Q_TGNCSPVDI-G\N>H.&
M(H^*%?7JB.U W03]-W@#;CJ4"VOJH]^]_:/)'Y@__?D_&(_I@^]RV^LZH$"0
M@#CDUF&M?E@_2CSD$+ADXD$QU[SUG..Q5"YF!%2?!U*/"F[@OWWA&G3P<^,.$'^6OV 7_GF[XEX _4B8=:[:_OL3:L
MPDWP_8?XAE\_Q*]"0+CY#3#!!@#UA$'+JU58,34^.,?S\JV&^,,\?6N+3
M@6%Z XL/D8@"1_U__6K^/,7'"1<_A1]-PQ"V_"@_P[TW(668:7PZN/Q>P__!
MRMB\CX\4YFD'\-9 S+VT^',TQY_^O>C"[/%VK=YNMD_JX93@_XWF=O"YRRU/
M_/IAXCUOO;OQO9Y\>PSXEV 3<.O?@KN7<,5;;QSXUYK#:"X>Q!WBV?30X[V;^";]=Y_?7%_?W7=.?N#W?W>N8<_+KX]7IUU
MOCZPJYNS-8?6GAW:&:R0RZTKVQ __Q##]<8V_G;-@1PG!W(FT27!+!>V@6;?
M>F,Y/-3JH![69=R=L^VERW5IV0:V&3[QV_<(-;X]G!\D!M<<<5)D*)V>.?V^
MZ>,0O8YMH!H#HQR V11O#C(TXCSSU#8M4'5N -HF'F8\I+3C;&IQWKNB"U2N,!]_1?_S)K>!-IMOF.IYL/+XUUD]>3" +#E>^#N@DO&@*
M: "=>M)*@??B<"12CE#RIV?$7W-7=QV$NY5-
MK36LO56-.%B'R?F,UV%JXN%:>$[@CI=";L5.H\675'M+$\C?Q3\44MM&U^*+
MIH&7NR88"G)08JY5=';UQZ2JG?YQ_*8/